Assessment of major gaps

Dec 19, 2019

Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.

Due to the increasing incidence and prevalence of neuroendocrine tumors (NETs), there is a need to assess any gaps in awareness and care. A survey was undertaken in 2017 to identify perceived unmet needs from the perspectives of patients/families, patient advocates and health care professionals (HCPs). The survey consisted of 33–37 questions (depending on type of respondent) across four areas: information, care, treatments and research.

Recent News

NICE approves Avelumab

NICE approves Avelumab

21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC.  Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...

read more
NICE launches their 2021-2026 strategy

NICE launches their 2021-2026 strategy

Yesterday, Monday April 19th, NICE launched their 2021-2026 strategy " a vision for the future".   According to NICE - Public and patients will see:   - An interactive guideline structure that facilitates links to the underpinning evidence and supports shared decision...

read more